Loading...
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.
Meyer, T Fox, R Ma, Y Ross, P James, M Sturgess, R Stubbs, C Stocken, D Wall, L Watkinson, A
Meyer, T
Fox, R
Ma, Y
Ross, P
James, M
Sturgess, R
Stubbs, C
Stocken, D
Wall, L
Watkinson, A
Citations
Altmetric:
Abstract
Transarterial chemoembolisation (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma, while the multikinase inhibitor sorafenib improves survival in patients with advanced disease. We aimed to determine whether TACE with sorafenib improves progression-free survival versus TACE with placebo.
Affiliation
Description
Date
2017-06-22
Publisher
Collections
Files
Keywords
Type
Article
Citation
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. 2017, 2:565-75 Lancet Gastroenterol Hepatol